Highlights
-
Live Today: Join us live as Dr. McGee breaks down top-performing peptide stacks, ideal patient profiles, and how to overcome the biggest barriers to integrating peptides into your orthopedic practice.
Add to your calendar and tune in at 5PM PST
- Today’s Research Article: PRP proves superior to shockwave therapy for hip bone death—offering longer-lasting pain relief and real functional gains.
- Questions from the Field: Does cellular therapy regrow cartilage? Not yet—but it may be slowing the damage.
- Let’s Get Down to Business: Want better patient communication in less time? Here’s how I connect clearly, compassionately—and get results.
- Come Join Us: Get hands-on, face-to-face, and ahead of the curve—don’t miss these top regenerative medicine events of 2025!
If this newsletter was forwarded to you and you'd like to receive future updates directly, subscribe here.
Today’s Research Article
Comparisons of Ultrasound-Guided Platelet-Rich Plasma Intra-Articular Injection and Extracorporeal Shock Wave Therapy in Treating ARCO I–III Symptomatic Non-Traumatic Femoral Head Necrosis: A Randomized Controlled Clinical Trial
Shuo Luan, Shaoling Wang, Caina Lin, Shengnuo Fan, Cuicui Liu, Chao Ma , Shaoling Wu
Summary:
This randomized controlled trial compared the effectiveness of ultrasound-guided intra-articular Platelet-Rich Plasma (PRP) injections with extracorporeal shock wave therapy (ESWT) in treating non-traumatic osteonecrosis of the femoral head (ONFH) in stages ARCO I–III. Over 12 months, patients receiving PRP showed significantly greater and longer-lasting improvements in pain relief (VAS), physical function (WOMAC, HHS), and pressure pain thresholds compared to those treated with ESWT. PRP’s benefits became statistically evident from month 3 onward and were maintained through the study duration. No significant adverse events were reported, confirming PRP’s safety.
The study highlights PRP’s regenerative and analgesic potential, especially for early-stage ONFH patients. It works by delivering a high concentration of growth factors that promote angiogenesis, reduce inflammation, and support joint repair. Compared to ESWT, PRP achieved larger improvements in pain and function while remaining a minimally invasive, drug-free, joint-preserving option. These results suggest that PRP can be a viable alternative to surgery or more invasive therapies, particularly for younger patients seeking to avoid joint replacement.
Doctor-to-Patient Talking Points on Why to Choose PRP (Based on the Study):
